April 3, 2014 - As a CEO/CFO or Investor how much debt is available to your company and how can the debt best be used to help build value in your company?
April 3, 2014 - A few years ago, a sociologist told me about a study of happiness in southern California. The top reported source of unhappiness was that people felt too busy and overwhelmed by all of their daily commitments, and that they did not get enough daily time alone for themselves.
April 3, 2014 - Eric Paley called me one evening to talk about an angel deal he was looking at. I was cooking dinner with my wife when he phoned. We talked about whether behavioral psychology could really work in convincing consumers to reduce their energy consumption.
March 19, 2014 - Enormous changes are afoot in the C-suite at companies at every level of scale and growth. We built Bowery Capital on the thesis that roughly $357 billion would change hands over the next ten years through the swapping out of old technology for new. This perspective comes from years of seeing internet natives becoming IT decision-makers, a concept on the rise, but this is something we are just at the beginning of. Greylock’s David Sze recently talked about finding companies to invest in that access the "$140 billion of IT spend up for grabs." We not only agree, but see the number as far higher. More specifically, we think we are only in the 1st or 2nd inning of this shift.
March 18, 2014 - Recently, I happened to be the third wheel of a conversation between two active angel investors who were talking about a particular company that was closing a round of funding (names will remain anonymous to protect the innocent). I was somewhat familiar with the company but not intimately; thus, I was able to listen to the debate –er, conversation – with a completely open mind.
March 18, 2014 - In this three part series, I will focus on the nuances of venture debt when applied to life science companies. Up first, the “black box” of life science lending–insight for companies and investors about what happens internally once the typical due diligence package is received. Next, in Part 2, I’ll cover how debt can add value, with a focus on biotech/pharma, medical devices and diagnostics/tools.The last installment, Part 3, will focus on the potential downside(s) to debt, and situations that are best funded by equity.